Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

England seeks views on including men in HPV vaccine programme

This article was originally published in Scrip

Executive Summary

Just as the UK's NHS prepares to switch from GlaxoSmithKline's human papillomavirus vaccine Cervarix to Sanofi Pasteur MSD's Gardasil, England's Joint Committee on Vaccination and Immunisation has put out a call for evidence on whether it should amend its HPV immunisation programme to include men. It will be considering how some men might benefit from vaccination and the potential impact of higher valency vaccines.

You may also be interested in...



Canada Counters Drug Shortages With Export Bans

Canada has announced new restrictions on exports to help mitigate the impact of measures in the US to lower medicine prices there.

The COVID-19 Economic Crisis – Fallout And Opportunities

In the wake of the COVID-19 pandemic and the ensuing economic fallout, pharmaceutical companies could face a range of measures designed to cut government spending on medicines. From relaxing intellectual property rights to delaying reimbursement, In Vivo examines what might be in store for industry.

Real World Data Failed To Impress Kaftrio’s European Reviewers

The European public assessment report for Kaftrio shows that EU regulators had concerns about whether Vertex’s triple drug combination for cystic fibrosis represented a new treatment paradigm.

Topics

Related Companies

UsernamePublicRestriction

Register

OM006664

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel